| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-198 | |
| Phytochemical name or plant extracts | Gypenoside LI | |
| PMID | 33716078 | |
| Literature evidence | CONCLUSIONS: These data indicate that gypenoside LI could inhibit human breast cancer cells through inhibiting proliferation and migration, inducing apoptosis, arresting cell cycle at G0/G1 phase by regulating E2F1. | |
| IUPAC name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(2R,3R,5R,8R,9R,10R,12R,13R,14R,17S)-2,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponin | |
| Source of phytochemicals or plant Extracts | Gynostemma pentaphyllum | |
| Geographical availability | Assam, Bangladesh, Borneo, China North-Central, China South-Central, China Southeast, East Himalaya, Hainan, Japan, Jawa, Korea, Kuril Is., Laos, Lesser Sunda Is., Malaya, Maluku, Myanmar, Nansei-shoto, Nepal, New Guinea, Philippines, Sri Lanka, Sulawesi, Sumatera, Thailand, Vietnam, West Himalaya | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | ERCC6L | |
| Gene or Protein evidence | Gypenoside LI exhibits antitumor activity through down-regulates the expression of ERCC6L in breast cancer cells | |
| Target pathways | NA | |
| IC50 | 42.988 μM against MDA-MB-231 66.843 μM against MCF-7 | |
| Potency | These data indicate that gypenoside LI could inhibit human breast cancer cells through inhibiting proliferation and migration, inducing apoptosis, arresting cell cycle at G0/G1 phase by regulating E2F1. | |
| Cell line/ mice model | MCF-7, MDA-MB-231 | |
| Additional information | Gypenoside LI arrested cell cycle at G0/G1 phase by regulating E2F1. It also inhibited tumor proliferation by regulating the expression of ERCC6L. Interestingly, we found that E2F1 siRNA also down-regulated the expression of ERCC6L. Gypenoside LI showed potential anti-breast cancer cells activity, especially on triple-negative breast cancer cells. | |
| PubChem ID | 76317290 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:292905-1 | |
| Safety | NA |